Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Declines By 63.2%

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 52,200 shares, a drop of 63.2% from the January 15th total of 141,800 shares. Currently, 3.1% of the shares of the stock are sold short. Based on an average daily volume of 422,400 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a report on Saturday, February 1st.

180 Life Sciences Stock Down 1.5 %

Shares of NASDAQ ATNF opened at $1.35 on Thursday. 180 Life Sciences has a 1-year low of $1.16 and a 1-year high of $17.75. The company has a 50-day moving average of $1.74 and a two-hundred day moving average of $2.15.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.